Genomics

OBiO Technology to Present Data on OVersatile™ Platform

OBiO Technology

OBiO Technology (Shanghai) Corp., Ltd. (‘OBiO’, SSE:688238.SH), a gene and cell therapy-focused biotechnology company, serving as a contract research organization for vectorology and functional genomics studies, and providing contract development and manufacturing services of IND-enabling CMC, clinical and commercial manufacturing, today announced that research on novel manufacturing technologies via its OVersatile™ platform will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual meeting on May 16-19, 2022 in Washington, D.C.

Empowered by robust manufacturing technologies and a comprehensive quality control system, the OVersatile™ platform enables flexible and high-quality process development and manufacturing solutions for a variety of gene and cell therapy products. Through research and development on novel manufacturing technologies with enhanced manufacturability, developability, and efficiency, the platform facilitates a high-titer, large-scale production capability and provides versatile development possibilities for various demands. The presentations highlight research on the upstream process development of herpes simplex virus and vaccinia virus products with the application of novel manufacturing technologies.

Details of the poster presentations:

Title: Development of Scalable Vaccinia Virus-Based Vector Production Process Using Dissolvable Porous Microcarriers
Session Date/Time: Monday, May 16, 2022, 5:30 p.m. – 6:30 p.m. EST
Session Title: Vector Product Engineering, Development or Manufacturing I
Abstract Number: 414
Poster Board Number: M-295

Title: High-Titer Herpes Simplex Virus Type 1-Based Vector Manufacturing Using Univercells Technologies’ Production System
Session Date/Time: Tuesday, May 17, 2022 5:30 p.m. – 6:30 p.m. EST
Session Title: Vector Product Engineering, Development or Manufacturing II
Abstract Number: 768
Poster Board Number: Tu-273

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

Related posts

Illumina Unveils Genomic Profiling Test for Cancer in Europe

PR Newswire

CosmosID® Announces Microbiome Partnership with Locus Biosciences

PR Newswire

Veracyte to Unveil Practice-Changing Genomic Diagnostics Data

Business Wire